New Cholesterol Drug Misses the Mark
Study Shows Pactimibe Did Not Slow Development of Clogged Arteries
Carotid artery thickening also worsened in the pactimibe group within one year.
Serious cardiovascular events occurred more frequently among the patients taking pactimibe than those taking the placebo; 2.3% of the patients in the pactimibe group experienced a heart attack, stroke, or death, compared to 0.2% in the placebo group. More patients in the pactimibe group also required hospitalization for chest pain, stent placement, heart bypass surgery, or carotid surgery during the study period.
The CAPTIVATE study is the third in a series of trials to show that ACAT-1 inhibitors have no effect on atherosclerosis, according to background information in the journal article. The researchers conclude that all the findings taken together lessen "the promise and further development of this class of drugs for cardiovascular prevention."
New Cholesterol Drug Misses the Mark
Study Shows Pactimibe Did Not Slow Development of Clogged Arteries
Study Terminated Early continued...
Carotid artery thickening also worsened in the pactimibe group within one year.
Serious cardiovascular events occurred more frequently among the patients taking pactimibe than those taking the placebo; 2.3% of the patients in the pactimibe group experienced a heart attack, stroke, or death, compared to 0.2% in the placebo group. More patients in the pactimibe group also required hospitalization for chest pain, stent placement, heart bypass surgery, or carotid surgery during the study period.
The CAPTIVATE study is the third in a series of trials to show that ACAT-1 inhibitors have no effect on atherosclerosis, according to background information in the journal article. The researchers conclude that all the findings taken together lessen "the promise and further development of this class of drugs for cardiovascular prevention."